Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.
Breast Cancer
DRUG: Epirubicin 90 mg/m2 iv|DRUG: Cyclophosphamide 600 mg/m2 iv|DRUG: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|DRUG: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|DRUG: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|DIETARY_SUPPLEMENT: Tocotrienol 300 mg x 3 daily
Pathological complete response, 26 weeks from date of inclusion
Correlation of changes in NK-cells with pathological complete response, 26 weeks from date of inclusion|Correlation of changes in ctDNA with pathological complete response, 26 weeks from date of inclusion|Number of patients with grade 3-4 side effects, 29 weeks from date of inclusion
The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.